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ABSTRACT
BACKGROUND: Overactive bladder (OAB) is a chronic condition affecting both
men and women, with prevalence increasing with age. Antimuscarinics form the cor-
nerstone of treatment of OAB. Fesoterodine, a nonselective muscarinic-receptor an-
tagonist, was approved by the US Food and Drug Administration in late 2008 for
once daily, oral administration in the treatment of OAB to relieve the symproms of
urinary urge incontinence, urgency, and frequency.
OBJECTIVE: The aim of this review was to provide an overview of the mecha-
nism ofaction ofand clinical trial data for fesoterodine, and ro discuss the present status
of fesoterodine in the management of OAB.
METHODS: The MEDLINE and Google Scholar databases were searched (Iune 1,
1999-December 1, 2009) using the terms fesoterodine, overactive bladder, and muscarinic
antagonists. Full-text articles in English were selected for reference, and articles pre-
senting the mechanism of action, pharmacokinetics, and data from clinical trials were
included. The parameters measured were tolerability, efficacy, and health-related
quality of life (HRQoL). Trials involving animals and Phase I studies were excluded.
RESULTS: The initial literature search yielded 48 papers. A total of 20 articles
fulfilled the inclusion criteria. In two 12-week, randomized, multicenter, Phase III
clinical trials involving patients with increased micturition frequency and urgency
and/or urinary urge incontinence (n = 836 and 1132 in each trial), both fesoterodine
4 and 8 mg were associated with significantly improved symptoms ofOAB (frequency
of micturition, urgency, and urge incontinence) compared with placebo (P < 0.05).
In a post hoc analysis of pooled data of the Phase III trials, HRQoL improved signifi-
cantly with both doses. In a 12-week, Phase IIIb trial, fesoterodine 4 and 8 mg led to
treatment satisfaction in -80% of patients (of 516 enrolled) who were initially unsat-
isfied with their previous treatment.
CONCLUSION: A review of the literature suggests that fesoterodine is an effica-
cious and well-tolerated treatment option for patients with OAB. (Curr Ther Res Clin
Exp. 2010;71:273-288) © 2010 Elsevier HS Journals, Inc.
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INTRODUCTION
Overactive bladder (OAB) has been defined by the Standardisation Sub-Committee of the
International Continence Society as urgency, with or without urge incontinence, usu-
ally with frequency and nocturia.' OAB is a highly prevalent symptom complex. In a
population-based survey of 16,776 men and women aged :2:40 years conducted by
Milsom et a1 2 in 6 countries, by telephone Ot direct interview, the prevalence of OAB
in Europe was estimated to be 15.6% in men and 17.4% in women, with an overall
prevalence of 16.6%. In a survey of 11,740 Americans, overall prevalence of OAB was
16.0% in men and 16.9% in wornen.f The symptoms and reduced quality of life
(QoL) associated with OAB cause distress in many patients.r OAB is a chronic condi-
tion occurring in both men and women, with a prevalence that increases with advanc-
ing age. The pathophysiology of OAB is complex. It is primarily caused by detrusor
overaetivity, defined as involuntary contractions of the detrusor muscle during the
bladder filling phase as a result of continuous and increasing afferent activity from the
bladder. 4 During normal function, the bladder should be relaxed as urine fills it. The
cause of OAB is unknown; however, 3 main theories of detrusor overacriviry have been
proposed. The myogenic theory suggests that partial denervarion of the detrusor re-
sults in alterations in the properties of the detrusor muscle cells leading to increased
excitability and, therefore, producing increases in involuntary pressure.? The neuro-
genic theory suggests that damage to central inhibitory pathways can unmask primi-
tive voiding reflexes that trigger detrusor overactivity.? A third theory, the autonomic
bladder hypothesis, was proposed in 2004.7 It suggests that detrusor overactivity is a
consequence of inappropriate activation or modulation of phasic activity.
OAB is not purely a bladder condition, but may also involve pelvic floor-muscle
dysfunction and behavioral issues." No drug can ever correct all facets of this multi-
factorial disorder. In almost all OAB groups, no curative treatment can be offered. The
principles of treatment are to increase voided volume, decrease urgency, and reduce
urinary urge incontinence (UUn episodes.f Current treatments include lifestyle inter-
ventions, bladder training and pelvic floor exercises, pharmacotherapy, and surgery."
Acetylcholine released from cholinergic nerves stimulates muscarinic receptors and
mediates the main part of the voiding contraction in humans.!" There are 5 different
subtypes of muscarinic receptors (MI-M5). They are all widely distributed through-
out the body. In the human bladder, the M2 and M3 receptors can be found, with the
ratio being 3:1, respectively. Despite the predominance ofM2 receptors, several inves-
tigators have found that the pharmacologically defined M3 receptors mediate bladder
contraction. The complexity of the muscarinic regulation of bladder function makes the
relative importance of the different muscarinic-receptor subrypes difficult to assess.
Antimuscarinic medications, aimed at blocking cholinergic-receptor activity in the
bladder, are the primary pharmacotherapeutic options for OAB. Currently, a variety of
antimuscarinics are used for the management of OAB: oxybutynin, tolterodine, propiv-
erine, solifenacin, darifenacin, and trospium chloride. 4 However, antimuscarinics are as-
sociated with adverse effects (AEs) (eg, constipation, dry mouth, blurred vision, drowsi-
ness) that impact both compliance and persistence with long-term treatment. None of
the currently available medications are ideal in terms of efficacy and tolerability. 11
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Fesorerodine is a novel, competitive, muscarin ic-receptor ant agonist that has re-
cently been approved for the tr eatment of OAB as a pro longed-release tabl et.12
The aim of th is review was to provi de an overview of the clinical tri al data for
fesorerod ine and its present status in the man agement of OAB .
METHODS
A search of the literature was performed using the MEDLINE and Goog le Scholar
databases with th e terms fesoterodine, ooeractiue bladder, and muscarinic antagonists. The
literat ure research was limited to Eng lish-language clinical tr ials , meta-analyses, ran-
domized cont rolled tr ials (RCTs), reviews, and conference abst racts pub lished from
June 1, 1999 to December 1, 2009 . Articles were required to present the mechanism
of action, pharmacokinet ics, and data from clini cal trials. T he parameters measured
were to lerabili ty, efficacy, and health-related QoL (H RQoL). Trials involving animals
and Ph ase I studies were excluded .
RESULTS
SEARCH RESULTS
The initial lit erat ure search yielded 48 papers. A tot al of 20 art icles fulfilling
the inclusion crite ria were selected . T hese included 4 each of Phase II , III , and IIIb
RCTs, 3 post hoc analyses, and 3 clinica l tr ials. In addition to th e full art icles, th e rele-
vant references of th e selected articles were obtained.
MECHANISM OF ACTION
Fesoterodine is a compet itive, specific, and nonselective muscarinic-receptor an-
tagonist . By prevent ing the binding of acetylcholine to th ese receptors, it reduces
smoo th -muscle tone in the bladder, allowing th e bladder to retain large r volumes of
urine and redu cing th e number of incontinence episodes. 13
CHEMISTRY
Fesoterodine is isobutyric acid 2-« R)-3-diisopropylammonium- l -phenylpropy l)-4-
(hydroxymethyl) phenyl ester hydrogen fumarate. The empirical formula is C30H41NOr
The structura l form ula is shown in the figure .14 .
PHARMACOKINETICS
Aft er ora l admin ist rat ion , fesot erodine is well absorbed . It acts as a prodrug.
It undergoes rapid and exte nsive hydrolysis by nonspecific plasma est erases to
for m its active metabo lite , 5-hyd roxymethyl rolr ercd ine (5 -HMT), whic h is re-
sponsib le for its antimuscarinic ac t iv ity.l ? S-H MT is also the act ive me taboli te
of rolr erodine, but th e metabol ism is med iated by cytoc hrom e P4 S0 (CY P) 2D6
in liver. Due to rapid conversion, fesote rodine cannot be detected in bl ood . Bio-
availabili ty of th e act ive metabolite is 52%. After si ngle or multi ple oral dai ly
doses from 4 to 28 mg, S-H MT exhi bits l inear, dose-propor t ional pharmacokinet -
ics. The T ma x of S-HMT is - 5 hours. No accu mulat ion occurs afte r multiple-dose
administrat ion.
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HO
Figure. Chemical structure of fesoterodine.14
Food does not appear to have a clinically relevant effect on the pharmacokinetics of
fesorerodine.J'' 5-HMT has low plasma protein binding (- 50%). The mean steady-
state volume of distribution after intravenous infusion of 5-HMT is 169 L l4
5-HMT is further metabolized in the liver via 2 major pathways involving
CYP2D6 and CYP3A4. None of the metabolites contribute significantly to the ami-
muscarinic activity of fesorerodine.I'' Metabolism via CYP2D6 varies in different in-
dividuals. The majority of the population are referred to as extensive merabolizers
while a subset of individuals (-7 % of whites and -2% blacks) are considered poor
rnetabolizers. The C
m ax
and AVC of 5-HMT are increased 1.7 and 2.0 times, respec-
tively, in poor metabolizers of CYP2D6 compared with extensive merabolizers.l?
However, mean T
m ax
and t 1l2 of5-HMT do not differ with regard to CYF2D6 rnerabo-
lizer status. Similarly, the extent of systemic accumulation at steady state is similar in
extensive and poor metabolizers. The elimination of 5-HMT depends on hepatic metabo-
lism and renal excretion. After oral administration of fesoterodine, -70% of the
administered dose is excreted in urine as metabolites and a smaller amount (-7%) is
recovered in the feces. The t 1/2 of 5-HMT following oral administration is -7 hours
and is -4 hours following intravenous infusion.!"
No apparent difference has been observed in the pharmacokinetics of fesoterodine
between healthy white or black subjecrs.l" The pharmacokinetics of fesorerodine are
not significantly influenced by age and gender and no dose adjustment is required. 12
The pharmacokinetics of fesoterodine have not been evaluated in pediatric patients.
In patients with mild or moderate renal insufficiency (creatinine clearance [CrCl}
of 30-80 mLlmin), C
m ax
of 5-HMT is increased up to 1.5 times compared with
healthy subjects. In patients with severe insufficiency (CrCi <30 mUmin), C
max
is
increased 2 times compared with healthy volunteers. 17 No dose adjustment is recom-
mended in patients with mild or moderate renal insufficiency. Therefore, a dose of
fesoterodine, up to 8 mg once daily, may be administered. However, in patients with
severe renal insufficiency, the recommended dose of 4 mg once daily should not be
exceeded. In patients with moderate (Child-Pugh B) hepatic impairment, C
m ax
and
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AUC of the 5-HMT are increased 1.4- and 2.1-fold, respectively, compared with
healthy subjects. No dose adjustment is recommended in patients with mild or mod-
erate hepatic impairment. Fesoterodine has not been srudied and is, therefore, not
recommended in patients with severe hepatic impairment (Child-Pugh C). IS
DRUG INTERACTIONS
To assess drug-drug interactions of fesorerodine, a CYP3A4 inhibitor (ketocon-
azole), inducer (rifampicin), and substrates (erhinyl esrradiol and levonorgestrel) were
administered. 19 Concomitant administration of keroconazole 200 mg twice daily with
fesoterodine 8 mg once daily resulted in a 2.0- and 2.3-fold increase in the C
max
and
AUC of 5-HMT in CYP2D6 extensive and poor metabolizers, respectively. Therefore,
the maximum dose of fesoterodine should be restricted ro 4 mg when used concomi-
tantly with potent CYP3A4 inhibitors such as keroconazole, itraconazole, and clarith-
romycin. The effects of weak or moderate CYP3A4 inhibitors have not been evaluated
in any study.l" Following concomitant administration of rifampicin 600 mg once a
day, C
max
and AUC of 5-HMT decreased by -70% and -75%, respectively, after oral
administration of fesoterodine 8 mg.t s Concomitant adminisrration of CYP3A4 in-
ducers may lead to subtherapeutic plasma levels. In the presence of fesoterodine, there
are no changes in the plasma concentrations of combined oral contraceptives contain-
ing ethinyl estradiol and levonorgesrrel.
Concomitant adminisrration of fesoterodine with other antimuscarinics and other
drugs with anticholinergic properties (eg, amantadine, tricyclic antidepressants) may
aggravate AEs such as constipation, dry mouth, drowsiness, and urinary retention.
Therefore, caution must be exercised while administering antimuscarinics to patients
already receiving fesoterodine.l''
FESOTERODINE CLINICAL TRIAL DATA
Clinical Efficacy
In a Phase II, multicenter, double-blind, randomized, placebo-controlled trial
by Nitti et al,2o the efficacy, tolerability, and dose-response relationship of
sustained-release fesoterodine were studied in patients with GAB (Table I). After
a I-week placebo run-in, 173 patients with ::>8 micturitions/24 hours and ::>2 UUI
episodes/week during the run-in period were randomized to receive fesoterodine 4,
8, or 12 mg, or placebo once daily for 8 weeks (44, 47,39, and 43 patients, respec-
tively). The primary efficacy end point was the number of micturitions per 24 hours.
The secondary efficacy end points were UUI episodes per week and mean volume
voided (MVV) per micturition. Dose-response relationship was described by fitting
a linear regression function test for a nonzero slope with power of::>80%. Multiple
regression analysis showed statistically significant linear dose-response improve-
ment from baseline and placebo in the primary efficacy variable. Statistically
significant improvement was observed with fesorerodine 4, 8, and 12 mg com-
pared with placebo (P < 0.04, P = 0.001, and P < 0.007, respectively). The
change from baseline to end of treatment in the MVV per micturition was 27.94,
58.96, and 92.34 mL in the fesoterodine 4-,8-, and l2-mg groups and 4.53 mL in
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the placebo group. Statistically significant changes in the secondary variables were
observed 2 weeks after randomization.
In a Phase III, double-blind, randomized, placebo-controlled, multicenter erial by
Nitti et al,21 the efficacy and tolerability of fesoterodine 4 and 8 mg were studied in
patients with GAB (Table II). Patients included men or women aged ::::18 years with
GAB symptoms for ::::6 months with urinary urgency (::::8 micturitions per 24 hours)
and UUI (::::6 episodes during the 3-day diary period) or ::::3 episodes of UUI during
the 3-day diary period. After a 2-week placebo run-in period, the eligible patients
were equally randomized to I of 3 groups: fesoterodine 4 mg once daily (n = 282;
females, 76%; mean age [range}, 59 [21-85} years), fesoterodine 8 mg once daily (n =
279; females, 78%; mean age [range}, 59 [23-9l} years), or placebo (n = 271; females,
74%; mean age [range}, 59 [24-88} years) for 12 weeks. Subjects completed a 3-day
bladder diary before randomization, and at 2, 8, and 12 weeks after initiating treat-
ment, in which the time of each micturition, incontinence episode, and urgency epi-
sode was recorded. Primary end points included the change from baseline in the
number of micturitions and the mean number of UUI episodes per 24 hours and the
treatment response, which was derived from a 4-point treatment benefit scale (l =
greatly improved; 2 = improved; 3 = not changed; and 4 = worsened during treat-
ment). The treatment benefit response was considered "Yes" if the score was 1 or 2;
"No" if the score was 3 or 4. Secondary efficacy end points were MVV per micturition,
and the number of daytime micturitions, nocturnal micturitions, and urgency epi-
sodes per 24 hours, and continent days per week. The mean change from baseline in
the number of micturitions per 24 hours was statistically significant with fesoterodine
8 mg (-2.09; P < 0.001) and fesorerodine 4 mg (-1.61; P = 0.032) compared with
that of placebo. The mean change from baseline in the number ofUUI episodes associ-
ated with fesoterodine 8 mg was -2.28 (P < 0.001 vs placebo) and -1.65 (P = 0.003
vs placebo) with fesoterodine 4 mg. Patient-reported treatment-response rates with
fesoterodine 8 mg (74%; P < 0.001) and fesoterodine 4 mg (64%; P < 0.001) were
statistically significantly higher compared with placebo (45%) at study end. With
respect to secondary end points, there was a statistically significant increase in MVV
per micturition with fesoterodine 8 mg (mean [SD}, 33.6 [4.0} mL; P < 0.001) and
no significant change with fesoterodine 4 mg (16.5 [4.0} mL) compared with placebo
(8.38 [4.l} mL). There was a statistically significant decrease in the number of daytime
micturitions associated with fesoterodine 8 mg (-1.54; P < 0.001 vs placebo) and no
significant change with fesoterodine 4 mg (-1.04). There was a statistically significant
decrease in the number of nocturnal micturitions associated with fesoterodine 4 mg
(-0.58; P = 0.013 vs placebo) but no statistical difference with fesorerodine 8 mg
(-25.0). Both fesoterodine doses led to a statistically significant decrease in the mean
number of urgency episodes (8 mg, -2.30 and 4 mg, -1.91; both, P < 0.001 vs placebo).
There was a statistically significant mean change in the number of continent days per
week both with 8 and 4 mg fesoterodine (2.80 and 2.33 days) compared with placebo
(1.31 days; both, P < 0.001).
In a Phase III, multicenter, randomized, 12-week, double-blind, placebo- and
active-controlled trial by Chapple et al,22 the efficacy, tolerability, and safety profile
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of fesoterodine were assessed in patients (N = 1132) with GAB (Table II). Patients
aged ~18 years with ~8 micturitions per 24 hours and either ~6 urgency episodes or
~3 UUI episodes per 24 hours were included in the study. After a 2-week placebo
run-in period, the eligible patients were equally randomized to 1 of 4 groups: fe-
soterodine 4 mg once daily (n = 272; female, 81 %; mean [SD} age, 57.1 [l3.2} years),
fesoterodine 8 mg once daily (n = 287; female, 82%; mean [SD} age, 55.6 [l4.1} years),
rolterodine extended release (ER) 4 mg once daily (n = 290; female, 78%; mean [SD} age,
57.7 [l4.6} years) and placebo (n = 283; female, 81 %; mean [SD} age, 56.0 [l3.7} years)
for 12 weeks. The primary efficacy end points were change from baseline to week 12
in micturitions per 24 hours, in UUI episodes per 24 hours, and treatment response
(which was identical to the primary efficacy end point of Nitti et aFl). Secondary ef-
ficacy end points included MVV per micturition, daytime micturitions per 24 hours,
nocturnal micturitions per 24 hours, urgency episodes per 24 hours, and continent days
per week (calculated based on a 3-day diary). At the end of treatment, there was a
statistically significant reduction in the least squares mean change in number of mic-
turitions per 24 hours from baseline in subjects receiving fesoterodine 4 mg (-1.76;
P < 0.001 vs placebo), fesoterodine 8 mg (-1.88; P < 0.001), and tolrerodine ER 4 mg
(-1.73; P = 0.001). The percentage of subjects who reported a positive treatment re-
sponse was statistically significantly higher among the subjects receiving fesoterodine
4 mg, fesoterodine 8 mg, and tolrerodine ER 4 mg, than placebo (75%, 79%, 72%,
and 53%, respectively; all, P < 0.001 vs placebo). At the end of treatment, the mean
change from baseline in UUI episodes per 24 hours was statistically significant for
patients receiving fesoterodine 4 mg (-1.95; P = 0.001 vs placebo), fesoterodine 8 mg
(-2.22; P < 0.00l), and rolterodine ER 4 mg (-1.74; P = 0.008). The increase in MVV
was 3.0, 3.6, and 2.5 times greater than placebo in subjects receiving fesoterodine
4 mg, 8 mg (both, P < 0.00l), and tolterodine ER 4 mg (P = 0.002), respectively.
The mean change in daytime micturitions was statistically significant with fe-
soterodine 4 and 8 mg and tolterodine ER 4 mg compared with placebo (all, P <
0.00l). The mean change in the number of urgency episodes per 24 hours was statisti-
cally significant with fesoterodine 4 mg (-1.88; P = 0.003 vs placebo), fesoterodine
8 mg (-2.36; P < 0.00l), and tolterodine ER 4 mg (-2.03; P < 0.001). The mean
increase in the number of continent days per week was statistically significant with
fesorerodine 4 mg (2.84; P = 0.007 vs placebo) and fesoterodine 8 mg (3.32; P <
0.001), but not significant with tolterodine ER 4 mg (2.48). The mean change in the
number of nocturnal micturitions per 24 hours was not statistically significant in any
of the groups compared with placebo.F
A post hoc analysis of Phase III trials by Khullar er aF3 suggested that fesoterodine
was associated with significantly reduced GAB symptoms, including urgency and
UUI, in a dose-dependent manner. Fesoterodine 8 mg was associated with a statisti-
cally significant improvement in most bladder-diary variables (P < 0.05) compared
with fesoterodine 4 mg, with the exception of micturition frequency, for which a nu-
merical, though not statistically significant, decrease was observed.
Another post hoc analysis by Chapple et al24 concluded that the maximum recom-
mended dose of fesoterodine (8 mg) was significantly (P < 0.05) more effective than
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the maximum recommended dose of tolterodine ER (4 mg) for improving several
important OAB outcomes including incontinence, MVV per void, number of conti-
nent days per week, and severe urgency plus UUI.
The efficacy and tolerability of flexible-dose fesoterodine in patients with OAB was
assessed by Wyndaele at al25 in a 12-week, multicenter, open-label, single-arm, flexible-
dose study (Table III). Patients aged ;:::18 years (n = 516; female, 77%; mean age,
60 years) with OAB symptoms for ;:::3 months, mean micturition frequency of;:::8 mic-
turitions per 24 hours, and mean number ofurgency episodes ;:::3 per 24 hours, who were
dissatisfied with previous tolterodine or tolterodine ER treatment (within 2 years of
screening) were enrolled. Patients reported being "somewhat dissatisfied" or "very dis-
satisfied" with tolterodine treatment on the treatment satisfaction question (TSQ), a
single item from the validated Overactive Bladder Satisfaction Questionnaire.f'' All of
these patients were administered fesoterodine 4 mg once daily for the first 4 weeks. After
that, the dose could either be maintained at 4 mg or increased to 8 mg once daily for
the remaining 8 weeks. Statistically significant improvements from baseline to week 12
were observed in the mean number of micturitions, UUI episodes, and urgency episodes
(all, P < 0.001). Statistically significant improvements in nocturnal micturitions, severe
urgency episodes, and frequency-urgency total were also observed at week 12 compared
with baseline (all, P < 0.001). After 12 weeks, 80% of patients who responded to the
TSQ reported being satisfied with fesoterodine, with 38% being "very satisfied." At that
time, 83% of subjects reported improvement on the Patient Perception of Bladder
Condition (PPBC) questionnaire.V The percentage of subjects with many severe, severe,
and moderate problems were 17.9%, 50.1 %, and 32.0%, respectively. After 12 weeks,
3.1 %,8.8%, and 24.6% had many severe, severe, and moderate problems. Also, 26.3%,
28.1 % and 9.0% of subjects had minor, very minor, or no problems. Mean PPBC scores
decreased (improved) significantly from 4.9 at baseline to 3.1 at week 12 (P < 0.001).
Improvement in mean scores on the Urgency Perception Scale28 was statistically signif-
icant at week 12 (from 1.8 at baseline to 2.4 at week 12; P < 0.001).
EFFECT ON HRQOL
A post hoc inferential analysis assessed treatment-related effects on HRQoL based on
the King's Health Questionnaire (KHQ),29 International Consultation on Incontinence
Table III. Table showing the results of the Phase IIIb trial. 25
282
Variable
Micturitions/24 h
Urgency episodes/24 h
Severe urgency episodes/24 h
UUI episodes/24 h
Nocturnal micturitions
UUI = urinary urge incontinence.
Mean No.
at Baseline
12.7
10.0
5.0
2.3
2.6
Mean No.
at Week 12
9.7
5.0
1.5
0.6
1.8
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Questionnaire Short Form (lCIQ-SF),30 and a 6-point Likert scale (0 = no problems to
5 = very severe problems), to rate the severity of problems related to their bladder
condit ion, and treatment response (a yes/no variable derived from a 4-point treatment-
benefit scale). Patients completed the scales at basel ine and end of study. The KHQ is
a 33-item , multidimensional, disease-specifi c qu esti onn aire with 9 domai ns: role
limitations, ph ysical lim itations, social limitations, personal relat ionships, emotions,
sleep/energy, severity/cop ing, incontinence impact , and general health percepti on.
Th e ICIQ-SF assesses the effects of urinary frequen cy and urine leakage on daily life.
The Likert scale assesses the bladder condit ion.
There was a statistically significant change in HRQoL in patients with OAB re-
ceiving fesoterodine 4 or 8 mg once daily compared with th ose receiving placebo. Th e
g roup that received fesoterodine 8 mg had statist ically sig nificant improvement s
compared with pl acebo in 8 of 9 KHQ domains (ie, all excep t for gene ral health per-
ception). Patients receiving fesoterodine 4 mg or tolterodine ER 4 mg had statistically
sig nificant improvements compared with placebo in 7 of 9 KHQ domains . Pati ent s
receiving fesoterodine 8 mg had sig nificantly better results than tho se receiving 4 mg
in 2 domains (ie, em ot ions and severity/coping; both , P < (>.05 ); however, th ere was
no sta ti st ically sig nificant difference between pati ent s receiving fesote rod ine 8 mg
and tho se receiving tolrerodine ER 4 mg. Improvem ents considered mean ingful to the
patients (ie, change from baseline of ~5 points) were found in all active treatment
g roups in all but one KHQ domai n (ie, genera l health percep t ion). All act ive treat-
ment g roups reported a sta t ist ically significant improvement in the ICIQ-SF score
compa red with placebo (P < 0.00 1), and there were no sta tist ical d ifferences between
active treatment g roups . At the end of the study, the Liker t scale scores ranged from
2.3 to 2.8 (indicating minor problems) compared with a mean of -3 .6 at th e baseline
(moderate to severe pro blems). The pe rcentage of patients wit h an improvement of
~2 points with fesoterodine 4 mg (33%), fesoterodine 8 mg (38 %), and tolterod ine
ER 4 mg (34 %) was sta tist ically sig nificant compared with pl acebo (all , P < 0 .00 I).
The percentage of patients reporting a positive treatment response was statist ically
significant in those receiving fesoterodine 4 or 8 mg once daily compared with those
receiving placebo (P < 0.001).'\1 \XTyndaele et al25 used the Overact ive Bladder Qu est ion-
naire (OAB_q),26 which comprises an 8-item Symptom Bother scale and a 25-item
H RQoL scale with 4 domains (concern, cop ing , sleep, and social interact ion). The mean
change in the OA B-q Symptom Bother score, in total HRQoL, and all 4 domains of
HRQoL from baseline to week 12 was statist ically signifi cant (all, P < 0 .00 1).
SAFETY AND TOLERABILITY
The safety and tol erab il it y profile of fesorerodi ne was stud ied in 3 Ph ase III
trials .21.22,25 In the Phase II tri al by Nitti er al ,20 th e safety pro file offesoterodine was
investigated . It was reported th at dr y mouth, headache, and gastrointestinal symp-
toms were the most common AEs. The treatment was di sconti nued by 2.27% , 4.25 %,
12.80 % , and 4.65% in pati ents receiving fesoterod ine 4 , 8, and 12 mg, and placebo,
respecti vely, due to AEs. The Phase III tr ial by Nitti et al21 reported that tre atment-
emergent AEs occurred in 6 1%, 69% , and 55% of subjects receiving fesoterodine 4
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and 8 mg, and placebo, respectively. The most frequently reported AE was mild to moder-
ate dry mouth, reported by 16%, 36%, and 7% of subjects in the fesoterodine 4 and
8 mg, and placebo groups. Urinary retention occurred in 1.41 %,2.15%, and 0.36%
of patients receiving fesoterodine 4 and 8 mg and placebo. Other reported AEs were
constipation, urinary tract infection, and headache. Chapple et al22 reported dry
mouth in 16.9%,21.7%,33.8%, and 7.15% of patients receiving tolterodine ER 4 mg,
fesoterodine 4 and 8 mg, and placebo. Severe dry mouth was reported by 3.0% of
patients in the 8-mg fesoterodine group. Other than dry mouth, no AE was reported in
> 5% of subjects. Other reported AEs were constipation, headache, and nasopharyngi-
tis. Wyndaele et al25 reported dry mouth (23%) and constipation (5%) as the most
common AEs. Urinary retention requiring catheterization was reported in one female
patient who was receiving fesoterodine 8 mg.
Fesoterodine treatment was not associated with any clinically relevant changes in
vital signs (eg, heart rate, blood pressure) Ot in laboratory parameters. Fesoterodine
4 and 8 mg once daily was generally well tolerated, and the number of patients who
discontinued due to the AEs was low in both clinical trials.21,22
DOSAGE AND ADMINISTRATION
Fesoterodine is indicated for the treatment of DAB to relieve symptoms of utge in-
continence, urgency, and frequency.14,18 The recommended starting dose of fesoterodine
is 4 mg once daily; however, it may be increased to 8 mg once daily depending on indi-
vidual response and rolerabihty.l" The daily dose of fesoterodine should not exceed
4 mg in patients with severe renal insufficiency (CrC! <30 rnL/min) and those taking
potent CYF3A4 inhibitors such as keroconazole, itraconazole, and clarithrornycin.l''
CONTRAINDICATIONS
Fesoterodine is contraindicated in patients with urinary retention, gastric reten-
tion, or uncontrolled narrow-angle glaucorna.lv-" It is also contraindicated in patients
with severe hepatic impairment (Child Pugh C) and known hypersensitivity to the
drug or its ingredients.
PRECAUTIONS
Caution needs ro be exercised in patients with the following: clinically significant
bladder outlet obstrucrion (risk of urinary retention); gastrointestinal obstructive
disorders (eg, pyloric stenosis); decreased gastrointestinal motility, such as those with
severe constipation; severe ulcerative colitis; toxic mega colon; myasthenia gravis; and
controlled narrow-angle glaucoma.
DISCUSSION
Based on this review of the literature, fesoterodine is a well-tolerated agent and the
pharmacokinetics of its active moiety, 5-HMT, are robust and largely independent of
CYP pharmacogenetics. The maximum recommended dose of fesoterodine (8 mg)
provided additional benefit compared with the maximum recommended dose of tol-
terodine ER (4 mg) on several important end points, including reduction in UUI epi-
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sodes and increase in MVV per void. Fesorerodine , which was g ranted US Food and
Drug Admini strat ion approval in October 2008, 32 is an addit ional treatment op tion
for pati ents with OAB . The Scottish Medicines Consorrium.P based on its assess-
ment , adv ises that fesorerodine should be used as a second-line agent in the National
Health Service for Scotl and in view of less expensive antirnuscarinics being available.
Fesoterodine is the newest oral drug available for treatment of OAB . Unlike the
CYP2D6-med iated metabolism of rolt erodine to 5-HMT, th e formation of 5-HMT
by fesoterodine is mediated by nonspecific and ubiquitous escerases.' ? Moreover, mul-
ti ple metabol ic (comparable cont ribu tions from CYP 3A4 and CYP2D6) and renal
excretion pathways are involved in the elimination of 5-HMT. Therefore, the effects
of patient intrinsic (hepati c/renal impairment) and extrinsic factors (CYP 3A4 or
CYP2D6 inhibition) on the pharmacokinetics of fesorerod ine are only modest. This
may generate an advantage compared wi th rolterodine.
A pooled post hoc analysis of the Phas e III trials21,22 found that fesoterodine 8 mg
was significantly more efficacious than fesoterodine 4 mg for improving UUI epi-
sodes , MVV per micturition , continent days per week, and subject-repon ed treatment
response after 12 weeks. The trial by W yndaele er al2s suggested similar results in th e
real- world clinical cond iti on . When fesoterodine was used in the flexible dos ing reg i-
men , rhere was a significant improvement in OAB sympto ms and HrQoL measures.
The clinical trials of fesorerodine have some limitat ions. First , th e onl y study with an
active comparator (rolterodine ER)22 was not powered to detect a statist ical difference
between fesoterodine and the comparator. Although the comparat ive results were not
available from this Phase III tr ial , th e open-label tri al by W yndaele et al found that ,
at 12 weeks, 80 % of subjects who responded to th e TSQ and who were dissatisfied with
their previous treatment (rolterodine ER), reported being satisfied with fesoterodine treat-
ment; 38% reported being very satisfied . Second, the durati on of the studies was just
12 weeks. Although supporti ve open-label extension studies are ongoing, it is difficult
to draw conclusions on efficacy from interim result s.14,34 Thi rd , the W yndaele et al
tri al was an open -label , nonrandomized, dose-escalation study without a control group .
Fourth, in the W ynd aele et al trial , no comparison was drawn between the sub ject s
who received the 4-mg dose th roughout the study with subjects who escalated to the
8-mg dose at week 4. Fifth, there were no data provided for the reasons for the dose
escalation in the same tr ial. Lasrly, in both the Phase III trials,21,n patients with OAB
of neurogenic orig in were not included , therefore lim iting the knowledge about the use
of fesoterodine in a very large group of patients with OAB .
The prolonged-release formulation of fesoterodine offers an advant age of less fre-
quent dosing and, consequently, better patient compliance. The benefit of pharmaco-
therapy for OAB must be a balance between efficacy and tolerability. The availability
of 2 different doses of fesorerodine (4 and 8 mg ) allows for an opportunity to find an
op timal balance between efficacy and tolerability in individ ual pat ients . The efficacy
of fesorerodine can be tested in pat ients unsati sfied with rolterodine trea tment .II
This was an attempt co review the available literature regarding fesorerodine, a
relati vely new molecule. A number of clinical trials are currenrly under way to explore
the efficacy, tolerabilit y, and safety pro file in compa rison with established treatments
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for OAB. A final word about th e use of fesorerodine would be possible once th e data
from th ese studies are available.
CONCLUSION
A review of the literature sugg ests that fesorerodine is an efficacious and well-tolerated
treatment op tion for pati ents with OAB .
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